1. Sodhi, A., S. Montaner, and J.S. Gutkind, Molecular mechanisms of cancer, in Signal Transduction and Human Disease, T. Finkel and J.S. Gutkind, Editors. 2003, John Wiley & Sons. p. 71-142.

2. Bogenrieder, T. and M. Herlyn, Axis of evil: molecular mechanisms of cancer metastasis. Oncogene, 2003. 22:6524-6536.

3. Zlotnik, A., Chemokines in neoplastic progression. Semin Cancer Biol, 2004. 14:181-185.

4. Smit, M.J., R.A. Bakker, and E.S. Burstein, G protein-coupled receptors and proliferative signaling. Methods Enzymol, 2002. 343:430-447.

5. Marinissen, M.J. and J.S. Gutkind, G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci, 2001. 22:368-376.

6. Heasley, L.E., Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene, 2001. 20:1563-1569.

7. Dhanasekaran, N., L.E. Heasley, and G.L. Johnson, G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev, 1995. 16:259-270.

8. Julius, D., T.J. Livelli, T.M. Jessell, and R. Axel, Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science, 1989. 244:1057-1062.

9. Launay, J.M., G. Birraux, D. Bondoux, J. Callebert, D. S. Choi, S. Loric, and L. Maroteaux, Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem, 1996. 271:3141-3147.

10. Allen, L.F., R.J. Lefkowitz, M.G. Caron, and S. Cotecchia, G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci USA, 1991. 88:11354-11358.

11. Gutkind, J.S., E.A. Novotny, M.R. Brann, and K.C. Robbins, Muscarinic acetylcho-line receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA, 1991. 88:4703-4707.

12. Bartholeyns, J. and M. Bouclier, Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase. Cancer Res, 1984. 44:639-645.

13. Takahashi, K., S. Tanaka, K. Furuta, and A. Ichikawa, Histamine H(2) receptor-mediated modulation of local cytokine expression in a mouse experimental tumor model. Biochem Biophys Res Commun, 2002. 297:1205-1210.

14. Kobayashi, K., S. Matsumoto, T. Morishima, T. Kawabe, and T. Okamoto, Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res, 2000. 60:3978-3984.

15. Diks, S.H., J.C. Hardwick, R.M. Diab, M.M. van Santen, H.H. Versteeg, S.J. van Deventer, D.J. Richel, and M.P Peppelenbosch, Activation of the canonical beta-catenin pathway by histamine. J Biol Chem, 2003. 278:52491-52496.

16. Heaney, A.P. and S. Melmed, Molecular targets in pituitary tumours. Nat Rev Cancer, 2004. 4:285-295.

17. Bevan, J.S. and J.R. Davis, Cabergoline: an advance in dopaminergic therapy. Clin Endocrinol (Oxf), 1994. 41:709-712.

18. Chun, J., E.J. Goetzl, T. Hla, Y. Igarashi, K.R. Lynch, W. Moolenaar, S. Pyne, and G. Tigyi, International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev, 2002. 54:265-269.

19. Mills, G.B. and W.H. Moolenaar, The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer, 2003. 3:582-591.

20. Umezu-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G.B. Mills, K. Inoue, J. Aoki, and H. Arai, Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol, 2002. 158:227-233.

21. Schafer, B., A. Gschwind, and A. Ullrich, Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene, 2004. 23:991-999.

22. Prescott, S.M., G.A. Zimmerman, D.M. Stafforini, and T.M. McIntyre, Platelet-activating factor and related lipid mediators. Annu Rev Biochem, 2000. 69:419-445.

23. Bussolati, B., L. Biancone, P Cassoni, S. Russo, M. Rola-Pleszczynski, G. Montrucchio, and G. Camussi, PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol, 2000. 157:1713-1725.

24. Camussi, G., G. Montrucchio, E. Lupia, A. De Martino, L. Perona, M. Arese, A. Vercellone, A. Toniolo, and F. Bussolino, Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol, 1995. 154:6492-6501.

25. Deo, D.D., N.G. Bazan, and J.D. Hunt, Activation of platelet-activating factor receptor-coupled G alpha q leads to stimulation of Src and focal adhesion kinase via two separate pathways in human umbilical vein endothelial cells. J Biol Chem, 2004. 279:3497-3508.

26. Portella, G., C. Laezza, P. Laccetti, L. De Petrocellis, V. Di Marzo, and M. Bifulco, Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J, 2003. 17:1771-1773.

27. Olias, G., C. Viollet, H. Kusserow, J. Epelbaum, and W. Meyerhof, Regulation and function of somatostatin receptors. J Neurochem, 2004. 89:1057-1091.

28. Asa, S.L. and S. Ezzat, The pathogenesis of pituitary tumours. Nat Rev Cancer, 2002. 2:836-849.

29. Shimon, I., X. Yan, J.E. Taylor, M.H. Weiss, M.D. Culler, and S. Melmed, Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas: novel potential therapy for functional pituitary tumors. J Clin Invest, 1997. 100:2386-2392.

30. Bruns, C., I. Lewis, U. Briner, G. Meno-Tetang, and G. Weckbecker, S0M230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol, 2002. 146:707-716.

31. Schally, A.V. and A. Nagy, Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab, 2004. 15:300-310.

32. Reubi, J.C., Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev, 2003. 24:389-427.

33. Themmen, A.P. and H.G. Brunner, Luteinizing hormone receptor mutations and sex differentiation. Eur J Endocrinol, 1996. 134:533-540.

34. Themmen, A.P., J.W. Martens, and H.G. Brunner, Activating and inactivating mutations in LH receptors. Mol Cell Endocrinol, 1998. 145:137-142.

35. Liu, G., L. Duranteau, J.C. Carel, J. Monroe, D.A. Doyle, and A. Shenker, Leydig cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. New Engl J Med, 1999. 341:1731-1736.

36. Paschke, R. and M. Ludgate, The thyrotropin receptor in thyroid diseases. New Engl J Med, 1997. 337:1675-1681.

37. Gutkind, J.S., Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene, 1998. 17:1331-1342.

38. McKenzie, J.M. and M. Zakarija, Clinical review 3: clinical use of thyrotropin receptor antibody measurements. J Clin Endocrinol Metab, 1989. 69:1093-1096.

39. Russo, D., F. Arturi, M. Schlumberger, B. Caillou, R. Monier, S. Filetti, and H.G. Suarez, Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene, 1995. 11:1907-1911.

40. Reubi, J.C., J.C. Schaer, and B. Waser, Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res, 1997. 57:1377-1386.

41. Gales, C., M. Poirot, J. Taillefer, B. Maigret, J. Martinez, L. Moroder, C. Escrieut, L. Pradayrol, D. Fourmy, and S. Silvente-Poirot, Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies. Mol Pharmacol, 2003. 63:973-982.

42. Olszewska-Pazdrak, B., K.L. Ives, J. Park, C.M. Townsend, Jr., and M.R. Hellmich, Epidermal growth factor potentiates cholecystokinin/gastrin receptor-mediated Ca2+ release by activation of mitogen-activated protein kinases. J Biol Chem, 2004. 279:1853-1860.

43. Clerc, P, C. Saillan-Barreau, C. Desbois, L. Pradayrol, D. Fourmy, and M. Dufresne, Transgenic mice expressing cholecystokinin 2 receptors in the pancreas. Pharmacol Toxicol, 2002. 91:321-326.

44. Clerc, P, S. Leung-Theung-Long, T.C. Wang, G.J. Dockray, M. Bouisson, M.B. Delisle, N. Vaysse, L. Pradayrol, D. Fourmy, and M. Dufresne, Expression of CCK2 receptors in the murine pancreas: proliferation, transdifferentiation of acinar cells, and neoplasia. Gastroenterology, 2002. 122:428-437.

45. Bagnato, A. and F. Spinella, Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab, 2003. 14:44-50.

46. Rosano, L., F. Spinella, D. Salani, V. Di Castro, A. Venuti, M.R. Nicotra, PG. Natali, and A. Bagnato, Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res, 2003. 63:2447-2453.

47. Lahav, R., C. Ziller, E. Dupin, and N.M. Le Douarin, Endothelin 3 promotes neural crest cell proliferation and mediates a vast increase in melanocyte number in culture. Proc Natl Acad Sci USA, 1996. 93:3892-3897.

48. Grant, K., M. Loizidou, and I. Taylor, Endothelin-1: a multifunctional molecule in cancer. Br J Cancer, 2003. 88:163-166.

49. Lahav, R., G. Heffner, and P.H. Patterson, An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA, 1999. 96:11496-11500.

50. Bagnato, A., L. Rosano, F. Spinella, V. Di Castro, R. Tecce, and P.G. Natali, Endo-thelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res, 2004. 64:1436-1443.

51. Kennedy, C., J. ter Huurne, M. Berkhout, N. Gruis, M. Bastiaens, W. Bergman, R. Willemze, and J.N. Bavinck, Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol, 2001. 117:294-300.

52. Valverde, P., E. Healy, S. Sikkink, F. Haldane, A.J. Thody, A. Carothers, I.J. Jackson, and J.L. Rees, The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet, 1996. 5:1663-1666.

53. Uemura, H., H. Ishiguro, N. Nakaigawa, Y. Nagashima, Y. Miyoshi, K. Fujinami, A. Sakaguchi, and Y. Kubota, Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther, 2003. 2:1139-1147.

54. Egami, K., T. Murohara, T. Shimada, K. Sasaki, S. Shintani, T. Sugaya, M. Ishii, T. Akagi, H. Ikeda, T. Matsuishi, and T. Imaizumi, Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest, 2003. 112:67-75.

55. Kirchgessner, A.L. and M. Liu, Orexin synthesis and response in the gut. Neuron, 1999. 24:941-951.

Rouet-Benzineb, P., C. Rouyer-Fessard, A. Jarry, V. Avondo, C. Pouzet, M. Yanag-isawa, C. Laboisse, M. Laburthe, and T. Voisin, Orexins acting at native OX1 receptor in colon cancer and neuroblastoma cells or at recombinant OX1 receptor suppress cell growth by inducing apoptosis. J Biol Chem, 2004. 279:45875-45886. Kojima, M., H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999. 402:656-660.

Korbonits, M., S.A. Bustin, M. Kojima, S. Jordan, E.F. Adams, D.G. Lowe, K. Kangawa, and A.B. Grossman, The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab, 2001. 86:881-887. Papotti, M., P. Cassoni, M. Volante, R. Deghenghi, G. Muccioli, and E. Ghigo, Ghrelin-producing endocrine tumors of the stomach and intestine. J Clin Endocrinol Metab, 2001. 86:5052-5059.

Jeffery, P.L., A.C. Herington, and L.K. Chopin, Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol, 2002. 172:R7-R11.

Holst, B., N.D. Holliday, A. Bach, C.E. Elling, H.M. Cox, and T.W. Schwartz, Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem, 2004. 279:53806-53817.

Dvorak, H.F., J.A. Nagy, B. Berse, L.F. Brown, K.T. Yeo, T.K. Yeo, A.M. Dvorak, L. van de Water, T.M. Sioussat, and D.R. Senger, Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci, 1992. 667:101-111.

Coughlin, S.R., Thrombin signalling and protease-activated receptors. Nature, 2000. 407:258-264.

Even-Ram, S., B. Uziely, P Cohen, S. Grisaru-Granovsky, M. Maoz, Y. Ginzburg, R. Reich, I. Vlodavsky, and R. Bar-Shavit, Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med, 1998. 4:909-914. Henrikson, K.P., S.L. Salazar, J.W. Fenton, 2nd, and B.T. Pentecost, Role of thrombin receptor in breast cancer invasiveness. Br J Cancer, 1999. 79:401-406. Booden, M.A., L.B. Eckert, C.J. Der, and J. Trejo, Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol, 2004. 24:1990-1999.

Tellez, C. and M. Bar-Eli, Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene, 2003. 22:3130-3137.

Ikeda, O., H. Egami, T. Ishiko, S. Ishikawa, H. Kamohara, H. Hidaka, S. Mita, and M. Ogawa, Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. Int J Oncol, 2003. 22:295-300.

Darmoul, D., V. Gratio, H. Devaud, and M. Laburthe, Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem, 2004. 279:20927-20934.

Murphy, P.M., International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev, 2002. 54:227-229.

Balkwill, F., Cancer and the chemokine network. Nat Rev Cancer, 2004. 4:540-550. Balkwill, F. and A. Mantovani, Inflammation and cancer: back to Virchow? Lancet, 2001. 357:539-545.

73. Milliken, D., C. Scotton, S. Raju, F. Balkwill, and J. Wilson, Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res, 2002. 8:1108-1114.

74. Yang, J. and A. Richmond, The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to gly-cosaminoglycan. Mol Ther, 2004. 9:846-855.

75. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S.N. Wagner, J.L. Barrera, A. Mohar, E. Verastegui, and A. Zlotnik, Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001. 410:50-56.

76. Murphy, PM., Chemokines and the molecular basis of cancer metastasis. New Engl J Med, 2001. 345:833-835.

77. Balkwill, F., The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol, 2004. 14:171-179.

78. Epstein, R.J., Opinion: the CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer, 2004. 4:901-909.

79. Wiley, H.E., E.B. Gonzalez, W. Maki, M.T. Wu, and S.T. Hwang, Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst, 2001. 93:1638-1643.

80. Murakami, T., W. Maki, A.R. Cardones, H. Fang, A. Tun Kyi, F.O. Nestle, and S.T. Hwang, Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res, 2002. 62:7328-7334.

81. Payne, A.S. and L.A. Cornelius, The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol, 2002. 118:915-922.

82. Robledo, M.M., R.A. Bartolome, N. Longo, J.M. Rodriguez-Frade, M. Mellado, I. Longo, G.N. van Muijen, P. Sanchez-Mateos, and J. Teixido, Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem, 2001. 276:45098-45105.

83. Kawada, K., M. Sonoshita, H. Sakashita, A. Takabayashi, Y. Yamaoka, T. Manabe, K. Inaba, N. Minato, M. Oshima, and M.M. Taketo, Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res, 2004. 64:4010-4017.

84. Balentien, E., B.E. Mufson, R.L. Shattuck, R. Derynck, and A. Richmond, Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene, 1991. 6:1115-1124.

85. Wang, D. and A. Richmond, Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem, 2001. 276:3650-3659.

86. Fishman, P, S. Bar-Yehuda, G. Ohana, F. Barer, A. Ochaion, A. Erlanger, and L. Madi, An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene, 2004. 23:2465-2471.

87. Madi, L., S. Bar-Yehuda, F. Barer, E. Ardon, A. Ochaion, and P Fishman, A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem, 2003. 278:42121-42130.

88. Pollock, PM., K. Cohen-Solal, R. Sood, J. Namkoong, J.J. Martino, A. Koganti, H. Zhu, C. Robbins, I. Makalowska, S.S. Shin, Y. Marin, K.G. Roberts, L.M. Yudt, A. Chen, J. Cheng, A. Incao, H.W. Pinkett, C.L. Graham, K. Dunn, S.M. Crespo-Carbone, K.R. Mackason, K.B. Ryan, D. Sinsimer, J. Goydos, K.R. Reuhl, M. Eckhaus, PS. Meltzer, W.J. Pavan, J.M. Trent, and S. Chen, Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet, 2003. 34:108-112.

89. Marin, Y.E. and S. Chen, Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med, 2004. 82:735-749.

90. Aramori, I. and S. Nakanishi, Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluRl, in transfected CHO cells. Neuron, 1992. 8:757-765.

91. Hamid, T. and S.S. Kakar, PTTG and cancer. Histol Histopathol, 2003. 18:245-251.

92. Tfelt-Hansen, J., P. Schwarz, E.F. Terwilliger, E.M. Brown, and N. Chattopadhyay, Calcium-sensing receptor induces messenger ribonucleic acid of human securin, pituitary tumor transforming gene, in rat testicular cancer. Endocrinology, 2003. 144:5188-5193.

93. Wodarz, A. and R. Nusse, Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol, 1998. 14:59-88.

94. Smalley, M.J. and T.C. Dale, Wnt signaling in mammalian development and cancer. Cancer Metastasis Rev, 1999. 18:215-230.

95. Rubinfeld, B., P Robbins, M. El-Gamil, I. Albert, E. Porfiri, and P. Polakis, Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science, 1997. 275:1790-1792.

96. Suzuki, H., D.N. Watkins, K.W. Jair, K.E. Schuebel, S.D. Markowitz, W. Dong Chen, T.P. Pretlow, B. Yang, Y. Akiyama, M. Van Engeland, M. Toyota, T. Tokino, Y. Hinoda, K. Imai, J.G. Herman, and S.B. Baylin, Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet, 2004. 36:417-422.

97. Rimm, D.L., K. Caca, G. Hu, F.B. Harrison, and E.R. Fearon, Frequent nuclear/cyto-plasmic localization of ß-catenin without exon 3 mutations in malignant melanoma. Am J Pathol, 1999. 154:325-329.

98. Vincan, E., Frizzled/WNT signaling: the insidious promoter of tumour growth and progression. Front Biosci, 2004. 9:1023-1034.

99. Lee, J.L., C.J. Chang, S.Y. Wu, D.R. Sargan, and C.T. Lin, Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands. Breast Cancer Res Treat, 2004. 84:139-149.

100. Lee, A.Y., B. He, L. You, S. Dadfarmay, Z. Xu, J. Mazieres, I. Mikami, F. McCormick, and D.M. Jablons, Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene, 2004. 23:6672-6676.

101. Müller, H.M., M. Oberwalder, H. Fiegl, M. Morandell, G. Goebel, M. Zitt, M. Mühlthaler, D. Öfner, R. Margreiter, and M. Widschwendter, Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet, 2004. 363:1283-1285.

102. Oberschmid, B.I., W. Dietmaier, A. Hartmann, E. Dahl, E. Klopocki, B.G. Beatty, N.H. Hyman, and H. Blaszyk, Distinct secreted Frizzled receptor protein 1 staining pattern in patients with hyperplastic polyposis coli syndrome. Arch Pathol Lab Med, 2004. 128:967-973.

103. Caldwell, G.M., C. Jones, K. Gensberg, S. Jan, R.G. Hardy, P Byrd, S. Chughtai, Y. Wallis, G.M. Matthews, and D.G. Morton, The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res, 2004. 64:883-888.

104. Stoehr, R., C. Wissmann, H. Suzuki, R. Knuechel, R.C. Krieg, E. Klopocki, E. Dahl, P. Wild, H. Blaszyk, G. Sauter, R. Simon, R. Schmitt, D. Zaak, F. Hofstaedter, A. Rosenthal, S.B. Baylin, C. Pilarsky, and A. Hartmann, Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest, 2004. 84:465-478.

105. Seto, E.S. and H.J. Bellen, The ins and outs of Wingless signaling. Trends Cell Biol, 2004. 14:45-53.

106. Miller, J.R., A.M. Hocking, J.D. Brown, and R.T. Moon, Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene, 1999. 18:7860-7872.

107. Brennan, K., J.M. Gonzalez-Sancho, L.A. Castelo-Soccio, L.R. Howe, and A.M. Brown, Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins. Oncogene, 2004. 23:4873-4784.

108. Uematsu, K., B. He, L. You, Z. Xu, F. McCormick, and D.M. Jablons, Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene, 2003. 22:7218-7221.

109. Uematsu, K., S. Kanazawa, L. You, B. He, Z. Xu, K. Li, B.M. Peterlin, F. McCormick, and D.M. Jablons, Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res, 2003. 63:4547-4551.

110. Chen, W., D. ten Berge, J. Brown, S. Ahn, L.A. Hu, W.E. Miller, M.G. Caron, L.S. Barak, R. Nusse, and R.J. Lefkowitz, Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science, 2003. 301:1391-1394.

111. Chen, W., L.A. Hu, M.V. Semenov, S. Yanagawa, A. Kikuchi, R.J. Lefkowitz, and W.E. Miller, beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. Proc Natl Acad Sci USA, 2001. 98:14889-14894.

112. Malbon, C.C., Frizzleds: new members of the superfamily of G-protein-coupled receptors. Front Biosci, 2004. 9:1048-1058.

113. Liu, T., A.J. DeCostanzo, X. Liu, H. Wang, S. Hallagan, R.T. Moon, and C.C. Malbon, G protein signaling from activated rat frizzled-1 to the b-catenin-Lef-Tcf pathway. Science, 2001. 292:1718-1722.

114. Ahumada, A., D.C. Slusarski, X. Liu, R.T. Moon, C.C. Malbon, and H.Y. Wang, Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP. Science, 2002. 298:2006-2010.

115. Slusarski, D.C., V.G. Corces, and R.T. Moon, Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signaling. Nature, 1997. 390:410-413.

116. Liu, T., X. Liu, H. Wang, R.T. Moon, and C.C. Malbon, Activation of rat frizzled-1 promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via pathways that require Gaq and Gao function. J Biol Chem, 1999. 274:33539-33544.

117. Liu, X., T. Liu, D.C. Slusarski, J. Yang-Snyder, C.C. Malbon, R.T. Moon, and H. Wang, Activation of a frizzled-2/beta-adrenergic receptor chimera promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via Gao and Gat. Proc Natl Acad Sci USA, 1999. 96:14383-14388.

118. Malbon, C.C., H. Wang, and R.T. Moon, Wnt signaling and heterotrimeric G-proteins: strange bedfellows or a classic romance? Biochem Biophys Res Commun, 2001. 287:589-593.

119. Wang, H.Y., WNT-frizzled signaling via cyclic GMP. Front Biosci, 2004. 9:1043-1047.

120. Li, H., C.C. Malbon, and H.Y. Wang, Gene profiling of Frizzled-1 and Frizzled-2 signaling: expression of G-protein-coupled receptor chimeras in mouse F9 teratocar-cinoma embryonal cells. Mol Pharmacol, 2004. 65:45-55.

121. Wang, H.Y. and C.C. Malbon, Wnt-frizzled signaling to G-protein-coupled effectors. Cell Mol Life Sci, 2004. 61:69-75.

122. Wang, H.Y. and C.C. Malbon, Wnt signaling, Ca2+, and cyclic GMP: visualizing Frizzled functions. Science, 2003. 300:1529-1530.

123. Kirikoshi, H., H. Sekihara, and M. Katoh, Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol, 2001. 19:111-115.

124. Iozzo, R.V., I. Eichstetter, and K.G. Danielson, Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res, 1995. 55:3495-3499.

125. Weeraratna, A.T., Y. Jiang, G. Hostetter, K. Rosenblatt, P. Duray, M. Bittner, and J.M. Trent, Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell, 2002. 1:279-288.

126. Mann, R.K. and PA. Beachy, Novel lipid modifications of secreted protein signals. Annu Rev Biochem, 2004. 73:891-923.

127. Gallet, A., R. Rodriguez, L. Ruel, and PP. Therond, Cholesterol modification of hedgehog is required for trafficking and movement, revealing an asymmetric cellular response to hedgehog. Dev Cell, 2003. 4:191-204.

128. Taipale, J., M.K. Cooper, T. Maiti, and PA. Beachy, Patched acts catalytically to suppress the activity of Smoothened. Nature, 2002. 418:892-897.

129. Ruel, L., R. Rodriguez, A. Gallet, L. Lavenant-Staccini, and P.P. Therond, Stability and association of Smoothened, Costal2 and Fused with cubitus interruptus are regulated by Hedgehog. Nat Cell Biol, 2003. 5:907-913.

130. Collier, L.S., K. Suyama, J.H. Anderson, and M.P. Scott, Drosophila costal 1 mutations are alleles of protein kinase A that modulate Hedgehog signaling. Genetics, 2004. 167:783-796.

131. Ingham, P.W. and A.P. McMahon, Hedgehog signaling in animal development: paradigms and principles. Genes Dev, 2001. 15:3059-3087.

132. DeCamp, D.L., T.M. Thompson, F.J. de Sauvage, and M.R. Lerner, Smoothened activates Gai-mediated signaling in frog melanophores. J Biol Chem, 2000. 275:26322-26327.

133. Murone, M., A. Rosenthal, and F.J. de Sauvage, Sonic hedgehog signaling by the patched-smoothened receptor complex. Curr Biol, 1999. 9:76-84.

134. Kasai, K., M. Takahashi, N. Osumi, S. Sinnarajah, T. Takeo, H. Ikeda, J.H. Kehrl, G. Itoh, and H. Arnheiter, The G12 family of heterotrimeric G proteins and Rho GTPase mediate Sonic hedgehog signalling. Genes Cells, 2004. 9:49-58.

135. Tojo, M., H. Kiyosawa, K. Iwatsuki, K. Nakamura, and F. Kaneko, Expression of the GLI2 oncogene and its isoforms in human basal cell carcinoma. Br J Dermatol, 2003. 148:892-897.

136. Kayed, H., J. Kleeff, S. Keleg, J. Guo, K. Ketterer, P.O. Berberat, N. Giese, I. Esposito, T. Giese, M.W. Buchler, and H. Friess, Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int J Cancer, 2004. 110:668-676.

137. Grachtchouk, V., M. Grachtchouk, L. Lowe, T. Johnson, L. Wei, A. Wang, F. de Sauvage, and A.A. Dlugosz, The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J, 2003. 22:2741-2751.

138. Xie, J., M. Murone, S.M. Luoh, A. Ryan, Q. Gu, C. Zhang, J.M. Bonifas, C.W. Lam, M. Hynes, A. Goddard, A. Rosenthal, E.H. Epstein, Jr., and F.J. de Sauvage, Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature, 1998. 391:90-92.

139. Couve-Privat, S., M. Le Bret, E. Traiffort, S. Queille, J. Coulombe, B. Bouadjar, M.F. Avril, M. Ruat, A. Sarasin, and L. Daya-Grosjean, Functional analysis of novel sonic hedgehog gene mutations identified in basal cell carcinomas from xeroderma pigmentosum patients. Cancer Res, 2004. 64:3559-3565.

140. Tabs, S. and O. Avci, Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol, 2004. 14:96-102.

141. Taipale, J., J.K. Chen, M.K. Cooper, B. Wang, R.K. Mann, L. Milenkovic, M.P. Scott, and P.A. Beachy, Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature, 2000. 406:1005-1009.

142. Karhadkar, S.S., G. Steven Bova, N. Abdallah, S. Dhara, D. Gardner, A. Maitra, J.T. Isaacs, D.M. Berman, and P.A. Beachy, Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature, 2004. 431:707-712.

143. Romer, J.T., H. Kimura, S. Magdaleno, K. Sasai, C. Fuller, H. Baines, M. Connelly, C.F. Stewart, S. Gould, L.L. Rubin, and T. Curran, Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+'- p53-'- mice. Cancer Cell, 2004. 6:229-240.

144. Berman, D.M., S.S. Karhadkar, A. Maitra, R. Montes De Oca, M.R. Gerstenblith, K. Briggs, A.R. Parker, Y. Shimada, J.R. Eshleman, D.N. Watkins, and P.A. Beachy, Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature, 2003. 425:846-851.

145. Qualtrough, D., A. Buda, W. Gaffield, A.C. Williams, and C. Paraskeva, Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment. Int J Cancer, 2004. 110:831-837.

146. Dahmane, N., P. Sanchez, Y. Gitton, V. Palma, T. Sun, M. Beyna, H. Weiner, and A. Ruiz i Altaba, The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development, 2001. 128:5201-5212.

147. Berman, D.M., S.S. Karhadkar, A.R. Hallahan, J.I. Pritchard, C.G. Eberhart, D.N. Watkins, J.K. Chen, M.K. Cooper, J. Taipale, J.M. Olson, and P.A. Beachy, Medullo-blastoma growth inhibition by hedgehog pathway blockade. Science, 2002. 297:1559-1561.

148. Athar, M., C. Li, X. Tang, S. Chi, X. Zhang, A.L. Kim, S.K. Tyring, L. Kopelovich, J. Hebert, E.H. Epstein, Jr., D.R. Bickers, and J. Xie, Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res, 2004. 64:7545-7552.

149. Sheng, T., C. Li, X. Zhang, S. Chi, N. He, K. Chen, F. McCormick, Z. Gatalica, and J. Xie, Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer, 2004. 3:29.

150. Kubo, M., M. Nakamura, A. Tasaki, N. Yamanaka, H. Nakashima, M. Nomura, S. Kuroki, and M. Katano, Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res, 2004. 64:6071-6074.

151. Sanchez, P., A.M. Hernandez, B. Stecca, A.J. Kahler, A.M. DeGueme, A. Barrett, M. Beyna, M.W. Datta, S. Datta, and A. Ruiz Altaba, Inhibition of prostate cancer proliferation by interference with Sonic Hedgehog-Gli-1 signaling. Proc Natl Acad Sci USA, 2004. 101:12561-12566.

152. Watkins, D.N. and C.D. Peacock, Hedgehog signalling in foregut malignancy. Bio-chem Pharmacol, 2004. 68:1055-1060.

153. Tas, S. and O. Avci, Rapid clearance of psoriatic skin lesions induced by topical cyclopamine: a preliminary proof of concept study. Dermatology, 2004. 209:126-131.

154. Frank-Kamenetsky, M., X.M. Zhang, S. Bottega, O. Guicherit, H. Wichterle, H. Dudek, D. Bumcrot, F.Y. Wang, S. Jones, J. Shulok, L.L. Rubin, and J.A. Porter, Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J Biol, 2002. 1:10.

155. Li, C., S. Chi, N. He, X. Zhang, O. Guicherit, R. Wagner, S. Tyring, and J. Xie, IFN alpha induces Fas expression and apoptosis in hedgehog pathway-activated BCC cells through inhibiting Ras-Erk signaling. Oncogene, 2004. 23:1608-1617.

Smit, M.J., C. Vink, D. Verzijl, P. Casarosa, C.A. Bruggeman, and R. Leurs, Virally encoded G protein-coupled receptors: targets for potentially innovative anti-viral drug development. Curr Drug Targets, 2003. 4:431-441.

Cesarman, E., R.G. Nador, F. Bai, R.A. Bohenzky, J.J. Russo, PS. Moore, Y. Chang, and D.M. Knowles, Kaposi's sarcoma-associated herpes virus contains G proteincoupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol, 1996. 70:8218-8223.

Guo, H.G., P. Browning, J. Nicholas, G.S. Hayward, E. Tschachler, Y.W. Jiang, M. Sadowska, M. Raffeld, S. Colombini, R.C. Gallo, and M.S. Reitz, Jr., Characterization of a chemokine receptor-related gene in human herpes virus 8 and its expression in Kaposi's sarcoma. Virology, 1997. 228:371-378.

Arvanitakis, L., E. Geras-Raaka, A. Varma, M.C. Gershengorn, and E. Cesarman, Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature, 1997. 385:347-350.

Rosenkilde, M.M., T.N. Kledal, H. Brauner-Osborne, and T.W. Schwartz, Agonists and inverse agonists for the herpes virus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem, 1999. 274:956-961. Smit, M.J., D. Verzijl, P. Casarosa, M. Navis, H. Timmerman, and R. Leurs, Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 consti-tutively activates p44/p42 MAPK and Akt via G(i) and phospholipase C-dependent signaling pathways. J Virol, 2002. 76:1744-1752.

Burger, M., J.A. Burger, R.C. Hoch, Z. Oades, H. Takamori, and I.U. Schraufstatter, Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpes virus-G protein-coupled receptor. J Immunol, 1999. 163:2017-2022.

Couty, J.P., E. Geras-Raaka, B.B. Weksler, and M.C. Gershengorn, Kaposi's sarcoma-associated herpes virus G protein-coupled receptor signals through multiple pathways in endothelial cells. J Biol Chem, 2001. 276:33805-33811.

Montaner, S., A. Sodhi, S. Pece, E.A. Mesri, and J.S. Gutkind, The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res, 2001. 61:2641-2648. Bais, C., B. Santomasso, O. Coso, L. Arvanitakis, E.G. Raaka, J.S. Gutkind, A.S. Asch, E. Cesarman, M.C. Gershengorn, E.A. Mesri, and M.C. Gerhengorn, G-protein-coupled receptor of Kaposi's sarcoma-associated herpes virus is a viral oncogene and angiogenesis activator. Nature, 1998. 391:86-89.

Yang, T.Y., S.C. Chen, M.W. Leach, D. Manfra, B. Homey, M. Wiekowski, L. Sullivan, C.H. Jenh, S.K. Narula, S.W. Chensue, and S.A. Lira, Transgenic expression of the chemokine receptor encoded by human herpes virus 8 induces an angioprolif-erative disease resembling Kaposi's sarcoma. J Exp Med, 2000. 191:445-454. Holst, P.J., M.M. Rosenkilde, D. Manfra, S.C. Chen, M.T. Wiekowski, B. Holst, F. Cifire, M. Lipp, T.W. Schwartz, and S.A. Lira, Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J Clin Invest, 2001. 108:1789-1796.

Sodhi, A., S. Montaner, V. Patel, J.J. Gomez-Roman, Y. Li, E.A. Sausville, E.T. Sawai, and J.S. Gutkind, Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpes virus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA, 2004. 101:4821-4826.

169. Beisser, PS., D. Verzijl, Y.K. Gruijthuijsen, E. Beuken, P. Koevoets, P. Prickaerts, M.J. Smit, R. Leurs, C.A. Bruggeman, and C. Vink, The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of PKR. J Virol, 2005. 79:441-449.

170. Casarosa, P, R.A. Bakker, D. Verzijl, M. Navis, H. Timmerman, R. Leurs, and M.J. Smit, Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem, 2001. 276:1133-1137.

171. Casarosa, P., Y.K. Gruijthuijsen, D. Michel, PS. Beisser, J. Holl, C.P Fitzsimons, D. Verzijl, C.A. Bruggeman, T. Mertens, R. Leurs, C. Vink, and M.J. Smit, Constitutive signaling of the human cytomegalovirus-encoded receptor UL33 differs from that of its rat cytomegalovirus homolog R33 by promiscuous activation of G proteins of the Gq, Gi, and Gs classes. J Biol Chem, 2003. 278:50010-50023.

172. Waldhoer, M., P Casarosa, M.M. Rosenkilde, M.J. Smit, R. Leurs, J.L. Whistler, and T.W. Schwartz, The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocyto-sis. J Biol Chem, 2003. 278:19473-19482.

173. Madden, S.L., B.P. Cook, M. Nacht, W.D. Weber, M.R. Callahan, Y. Jiang, M.R. Dufault, X. Zhang, W. Zhang, J. Walter-Yohrling, C. Rouleau, V.R. Akmaev, C.J. Wang, X. Cao, T.B. St Martin, B.L. Roberts, B.A. Teicher, K.W. Klinger, R.V. Stan, B. Lucey, E.B. Carson-Walter, J. Laterra, and K.A. Walter, Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol, 2004. 165:601-608.

174. Young, D., G. Waitches, C. Birchmeier, O. Fasano, and M. Wigler, Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell, 1986. 45:711-719.

175. Okumura, S., H. Baba, T. Kumada, K. Nanmoku, H. Nakajima, Y. Nakane, K. Hioki, and K. Ikenaka, Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci, 2004. 95:131-135.

176. Weigle, B., S. Fuessel, R. Ebner, A. Temme, M. Schmitz, S. Schwind, A. Kiessling, M.A. Rieger, A. Meye, M. Bachmann, M.P. Wirth, and E.P. Rieber, D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun, 2004. 322:239-249.

177. Sin, W.C., Y. Zhang, W. Zhong, S. Adhikarakunnathu, S. Powers, T. Hoey, S. An, and J. Yang, G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overex-pressed in human cancers. Oncogene, 2004. 23:6299-6303.

178. Harms, J.F., D.R. Welch, and M.E. Miele, KISS1 metastasis suppression and emergent pathways. Clin Exp Metastasis, 2003. 20:11-18.

179. Leurs, R., M.J. Smit, A.E. Alewijnse, and H. Timmerman, Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem Sci, 1998. 23:418-422.

180. Schöneberg, T., A. Schulz, H. Biebermann, T. Hermsdorf, H. Römpler, and K. Sangkuhl, Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacology & Therapeutics, 2004. 104:173-206.

How To Prevent Skin Cancer

How To Prevent Skin Cancer

Complete Guide to Preventing Skin Cancer. We all know enough to fear the name, just as we do the words tumor and malignant. But apart from that, most of us know very little at all about cancer, especially skin cancer in itself. If I were to ask you to tell me about skin cancer right now, what would you say? Apart from the fact that its a cancer on the skin, that is.

Get My Free Ebook

Post a comment